We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Idera Pharmaceuticals Inc | NASDAQ:IDRA | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.425 | 0.432 | 0.48 | 0 | 01:00:00 |
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue.
See
Instruction 1(b).
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
|
OMB APPROVAL
OMB Number: 3235-0287 Estimated average burden hours per response... 0.5 |
|
|
|
1. Name and Address of Reporting Person
*
BAKER BROS. ADVISORS LP |
2. Issuer Name
and
Ticker or Trading Symbol
IDERA PHARMACEUTICALS, INC. [ IDRA ] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director __ X __ 10% Owner _____ Officer (give title below) _____ Other (specify below) |
860 WASHINGTON STREET, 3RD FLOOR |
3. Date of Earliest Transaction
(MM/DD/YYYY)
|
|
NEW YORK, NY 10014 |
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
___ Form filed by One Reporting Person _ X _ Form filed by More than One Reporting Person |
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned |
||||||||||
1.Title of Security
(Instr. 3) |
2. Trans. Date | 2A. Deemed Execution Date, if any |
3. Trans. Code
(Instr. 8) |
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) |
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) |
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |||
Code | V | Amount | (A) or (D) | Price | ||||||
Common Stock | 4288031 | I | See footnotes (1) (8) (9) | |||||||
Common Stock | 6/6/2019 | J (2) | 178967 | D | $0 (2) | 347757 | I | See footnotes (4) (8) (9) | ||
Common Stock | 6/6/2019 | J (3) | 59267 | D | $0 (3) | 0 | I | See footnotes (5) (8) (9) | ||
Common Stock | 6/6/2019 | J | 21929 | A | $0 | 21929 (6) | D | |||
Common Stock | 6/6/2019 | J | 21929 | A | $0 | 21929 (7) | D |
Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) |
|||||||||||||||
1. Title of Derivate Security
(Instr. 3) |
2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any |
4. Trans. Code
(Instr. 8) |
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) |
6. Date Exercisable and Expiration Date |
7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) |
8. Price of Derivative Security
(Instr. 5) |
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | ||||
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||||||
Warrants to purchase Common Stock | $0.08 | 6/6/2019 | J | 42724 | 5/7/2013 | 5/7/2020 | Common Stock | 42724 | $0 | 0 | I | See Footnote (10) | |||
Warrants to purchase Common Stock | $0.08 | 6/6/2019 | J | 11337 | 9/25/2013 | 9/30/2020 | Common Stock | 11337 | $0 | 0 | I | See Footnote (10) | |||
Warrants to purchase Common Stock | $0.08 | 6/6/2019 | J | 6009 | 2/5/2014 | 2/10/2021 | Common Stock | 6009 | $0 | 0 | I | See Footnote (10) | |||
Warrants to purchase Common Stock | $0.08 | 6/6/2019 | J | 6256 | 5/7/2013 | 5/7/2020 | Common Stock | 6256 | $0 | 6256 (11) | D | ||||
Warrants to purchase Common Stock | $0.08 | 6/6/2019 | J | 1660 | 9/25/2013 | 9/30/2020 | Common Stock | 1660 | $0 | 1660 (11) | D | ||||
Warrants to purchase Common Stock | $0.08 | 6/6/2019 | J | 880 | 2/5/2014 | 2/10/2021 | Common Stock | 880 | $0 | 880 (11) | D | ||||
Warrants to purchase Common Stock | $0.08 | 6/6/2019 | J | 6256 | 5/7/2013 | 5/7/2020 | Common Stock | 6256 | $0 | 6256 (12) | D | ||||
Warrants to purchase Common Stock | $0.08 | 6/6/2019 | J | 1660 | 9/25/2013 | 9/30/2020 | Common Stock | 1660 | $0 | 1660 (12) | D | ||||
Warrants to purchase Common Stock | $0.08 | 6/6/2019 | J | 880 | 2/5/2014 | 2/10/2021 | Common Stock | 880 | $0 | 880 (12) | D |
Remarks:
Remarks: Effective June 4, 2019 Kelvin M. Neu resigned from the board of directors of Idera Pharmaceuticals, Inc. |
Reporting Owners
|
|||||
Reporting Owner Name / Address |
|
||||
Director | 10% Owner | Officer | Other | ||
BAKER BROS. ADVISORS LP
860 WASHINGTON STREET 3RD FLOOR NEW YORK, NY 10014 |
|
X |
|
|
|
Baker Bros. Advisors (GP) LLC
860 WASHINGTON STREET 3RD FLOOR NEW YORK, NY 10014 |
|
X |
|
|
|
BAKER FELIX
860 WASHINGTON STREET 3RD FLOOR NEW YORK, NY 10014 |
|
X |
|
|
|
BAKER JULIAN
860 WASHINGTON STREET, 3RD FLOOR NEW YORK, NY 10014 |
|
X |
|
|
Signatures
|
||
By: Baker Bros. Advisors LP, Name: Scott L. Lessing, Title: President /s/ Scott L. Lessing | 6/7/2019 | |
** Signature of Reporting Person |
Date
|
|
By: Baker Bros. Advisors (GP) LLC, Name: Scott L. Lessing, Title: President /s/ Scott L. Lessing | 6/7/2019 | |
** Signature of Reporting Person |
Date
|
|
/s/ Felix J. Baker | 6/7/2019 | |
** Signature of Reporting Person |
Date
|
|
/s/ Julian C. Baker | 6/7/2019 | |
** Signature of Reporting Person |
Date
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | |
* | If the form is filed by more than one reporting person, see Instruction 4(b)(v). |
** | Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
Note: | File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. |
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. |
1 Year Idera Pharmaceuticals Chart |
1 Month Idera Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions